CoChat

Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis

Open access
Luna, Laura E. Moreno, Gores, Gregory J. · 2006 · Liver Transplantation
Cited by 38

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic liver disease characterized by inflammatory destruction of the biliary tree. It slowly progresses, resulting in biliary fibrosis and obliteration leading to end-stage liver disease. The most feared complication of PSC is the development of cholangiocarcinoma (CCA).1 The prevalence of CCA in patients with PSC ranges 4.8-36.4%.2-7 PSC is the most common known predisposing factor for CCA in the United Kingdom (lifetime risk 5-15%).8 It has been reported that the incidence of developing CCA in patients with PSC is 0.6-1.5% per year.9, 10 The highest incidence is the first 2 years after the diagnosis of PSC. Indeed, in 37-50% of patients with PSC who develop CCA, the diagnosis of malignancy was made within the first year after the diagnosis of PSC.10, 11 Either only a certain subset of patients with PSC are at risk for the development of CCA and do so early in the course of their disease, or many patients have symptomatic, difficult-to-diagnose CCA at presentation. CCA in patients with PSC has an onset about 3 decades earlier than CCA in patients without PSC.12 The cholangiographic findings and clinical symptoms of CCA are nonspecific and are difficult to differentiate from benign dominant bile duct strictures, which are common in PSC.13 Therefore, CCA in the setting of PSC remains difficult to diagnose. It is often found at autopsy as an advanced stage of disease, or unexpectedly at the time of liver transplantation.10, 12, 14 Several risk factors have been proposed to increase the occurrence of CCA in patients with PSC: smoking,15 alcohol,16 older age at onset of PSC,10 and a longer history of inflammatory bowel disease before diagnosis of PSC.11 Unlike the risks of ulcerative colitis and colon cancer, the risk of developing CCA does not appear to be related to the duration of PSC. However, patients with PSC with a history of colorectal dysplasia or cancer in the setting of concomitant inflammatory bowel disease are at increased risk for developing CCA. Ursodeoxycholic acid therapy may reduce the risk of CCA in PSC, as it does for colorectal neoplasia in inflammatory bowel disease.17 In a Swedish study, patients with PSC had an increased risk of pancreatic carcinoma compared with the general population. None of the patients had a known history of chronic pancreatitis.10 However, this finding has not been replicated, and it is difficult to differentiate distal bile duct CCA from pancreatic cancer. Thus, the risk of pancreatic cancer in PSC is unclear. PSC, primary sclerosing cholangitis; CCA, cholangiocarcinoma; CA, carbohydrate antigen; MRI, magnetic resonance imaging; DIA, digital image analysis; FISH, fluorescence in situ hybridization. Extra- and intrahepatic CCA have distinct clinical presentations. Extrahepatic CCAs arise in the left and right hepatic ducts, common hepatic ducts, and common bile ducts, and they present with features of biliary obstruction. Such an identifiable stricture causing biliary obstruction in a patient with PSC is often referred to as a "dominant stricture," and the problem is differentiating a malignant from a benign inflammatory stricture. Intrahepatic CCA occurs within the hepatic parenchyma, develops as an intrahepatic mass lesion, and frequently presents with advanced signs and symptoms (abdominal pain, weight loss, anorexia). In patients with PSC, CCA usually develops as an extrahepatic tumor rather than as an intrahepatic mass.1 From a cohort of 394 patients with PSC, the mean age at diagnosis of PSC was comparable in patients with CCA (40.7 ± 12.7 years) and without CCA (38.4 ± 15.1 years) (P = 0.192). Jaundice, pruritus, fatigue, and abdominal pain were markedly more frequent among patients with CCA.11 Weight loss, fever, cholangitis, hepatomegaly, splenomegaly, and ascites were present but were not markedly more frequent compared with patients who did not develop CCA.11 On the basis of clinical symptoms alone, it is difficult to differentiate advanced PSC from PSC with superimposed CCA. Many experienced clinicians, however, base their suspicion of CCA on the rate of development of the symptoms described above. The sudden onset of jaundice, malaise, pruritus, and weight loss is more worrisome for CCA that the slow, insidious onset of such symptoms over time. There is no specific tumor marker for the diagnosis of CCA in patients with PSC. The best serum test is the carbohydrate antigen 19-9 (CA 19-9). A CA 19-9 with a cutoff of 129 U/mL provides a sensitivity of 78.6%, specificity of 98.5%, adjusted positive predictive value of 56.6%, and negative predictive value of 99.4%. In this study, only 2 patients with CCA were candidates for curative therapy.18 Thus, a markedly elevated serum CA 19-9 value usually signifies advanced malignant disease. Further, bacterial cholangitis results in elevated serum CA 19-9 values, which diminishes the specificity of this test. CEA alone and in combination with CA 19-

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/lt.20938

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 38

Metadata

Authors
Luna, L. E. M., & Gores, G. J.
Venue
Liver Transplantation
Published
2006-11
Volume
12
Issue
Supplement 2
Pages
S15-S19
ISSN
1527-6465 (ISSN-L)
OpenAlex
W1975981062
Cited by
38
References
3
FWCI
3.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.